{"id":"NCT02432807","sponsor":"Kurobe LLC","briefTitle":"Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis","officialTitle":"A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2018-05-31","completion":"2018-05-31","firstPosted":"2015-05-04","resultsPosted":"2024-10-23","lastUpdate":"2024-10-23"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Vancomycin 1.1%","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vancomycin 1.1%","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive bacterial conjunctivitis.","primaryOutcome":{"measure":"Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis","timeFrame":"8 days","effectByArm":[{"arm":"Vancomycin 1.1%","deltaMin":71,"sd":null},{"arm":"Placebo","deltaMin":59,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2219"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":152},"commonTop":["Headache","Punctate keratitis","Pyrexia","Vomiting","Dry eye"]}}